Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 217 participants.
Also called NCT01739400
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 217 participants
- Sponsor
- Registry
-
NCT01739400
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Chile, China, France, Germany, Greece, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Russia, Serbia, Spain, United Kingdom, Vietnam
- Registry status
- Terminated
Technical summary
Registry record NCT01739400. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-01-12 (actual). Results posted on 2019-04-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
- Acronym
- MAESTRO-OL
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Macitentan 10 mg tablet, once daily.
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct01739400- Content hash
2fef3bda5957b8ffa52c1122dc5a89d8c002754fdd560f058d7052801edb9f6c